Sanofi Upbeat On Itepekimab, Rilzabrutinib And Oral IRAK4 Protein Degrader
15 Immunologics In Active Development
Sanofi outlines progress on developing a differentiated R&D pipeline in immunology, including novel ways of addressing COPD, atopic dermatitis and autoimmune disorders.
